Resectable Non-small Cell Lung Cancer Clinical Trials

16 clinical trials for Resectable Non-small Cell Lung Cancer across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) — RECRUITING · PHASE1
• A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC — RECRUITING · PHASE2
• An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany — RECRUITING
• A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery — ACTIVE_NOT_RECRUITING · PHASE2
• AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer — NOT_YET_RECRUITING · PHASE2
• Study of Novel Treatment Combinations in Patients With Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• A phase III clinical trial of adjuvant treatment with Sacituzumab and Zimberelimab for stage IB-IIIA-IIIB (N2) previously resected (R0) non-small cell lung cancer (NSCLC) patients that did not achieve pathological complete response after neoadjuvant treatment (ARIAN) — TERMINATED · PHASE3
• A phase III clinical trial of adjuvant chemotherapy vs chemo-immunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients_NADIM-ADJUVANT — TERMINATED · PHASE3
• NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC — NOT_YET_RECRUITING · PHASE1
• Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab — WITHDRAWN · PHASE2
• A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC — NOT_YET_RECRUITING · PHASE2
• Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study — NOT_YET_RECRUITING · PHASE2
• Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC — NOT_YET_RECRUITING · NA
• A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC — OTHER · PHASE3
• Mechanism of Action Trial of ColoAd1 — COMPLETED · PHASE1

Refine this search